Adimune

About Aditxt

Aditxt is a U.S.-based biotech firm developing technologies to monitor and modulate the immune system through its two core platforms: AditxtScore for immune profiling and Adimune for inducing immune tolerance. Its mission is to translate immune insights into therapies for autoimmune disorders and transplant rejection, with a pipeline primarily in preclinical and early clinical stages. The company faces significant challenges, including extreme stock volatility indicative of financial distress, a pre-revenue status requiring continual capital, and the high-risk nature of developing novel immunology platforms in a crowded competitive landscape.

About Aditxt

Aditxt is a U.S.-based biotech firm developing technologies to monitor and modulate the immune system through its two core platforms: AditxtScore for immune profiling and Adimune for inducing immune tolerance. Its mission is to translate immune insights into therapies for autoimmune disorders and transplant rejection, with a pipeline primarily in preclinical and early clinical stages. The company faces significant challenges, including extreme stock volatility indicative of financial distress, a pre-revenue status requiring continual capital, and the high-risk nature of developing novel immunology platforms in a crowded competitive landscape.

About Aditx Therapeutics

Aditxt, Inc. is a publicly traded biotechnology company founded in 2018 with a mission to improve immune system health and address pressing health challenges. Its core strategy involves acquiring innovative companies and leveraging its proprietary 'aditXt' business acceleration platform to de-risk and scale these assets. The company's current portfolio includes programs in autoimmunity, early cancer detection, and neurological diagnostics, with a pipeline built entirely through acquisition and partnership.

Therapeutic Areas

Other Vitiligo Drugs